Made up of an exciting team of multinational researchers, the Black Swan Research Initiative® team has developed a way to monitor the status of myeloma at very low levels, or minimal residual disease (MRD). By developing accurate testing to identify MRD, treatment efforts to rid the body of the disease entirely can be enhanced. During 2016, the Black Swan team developed such a test, known as Next Generation Flow. In this video, Dr. Brian Durie reveals where NGF stands today worldwide, and also discusses other key BSRI team projects, including iStopMM and the ASCENT trial.
If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected].
To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected].
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.
